URGN (UroGen Pharma) Total Equity : $-8.80 Mil (As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is UroGen Pharma Total Equity?

UroGen Pharma's total equity for the quarter that ended in Dec. 2024 was $-8.80 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

UroGen Pharma Total Equity Historical Data

The historical data trend for UroGen Pharma's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

UroGen Pharma Total Equity Chart

UroGen Pharma Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Equity

Get a 7-Day Free Trial

96.36

8.41

-89.36

-65.21

-8.80

UroGen Pharma Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Equity	Get a 7-Day Free Trial															-65.21	-40.13	30.31	25.52	-8.80

UroGen Pharma Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

UroGen Pharma's Total Equity for the fiscal year that ended in Dec. 2024 is calculated as

Total Equity	=	Total Assets(Q: Dec. 2024 )	-	Total Liabilities(Q: Dec. 2024 )
	=	285.711	-	294.514
	=	-8.80

UroGen Pharma's Total Equity for the quarter that ended in Dec. 2024 is calculated as

Total Equity	=	Total Assets(Q: Dec. 2024 )	-	Total Liabilities(Q: Dec. 2024 )
	=	285.711	-	294.514
	=	-8.80

UroGen Pharma Total Equity Related Terms

Thank you for viewing the detailed overview of UroGen Pharma's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

UroGen Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UroGen Pharma Ltd (NAS:URGN) » Definitions » Total Equity

Comparable Companies

Traded in Other Exchanges

0XOD:UK UR8:Germany

Address

400 Alexander Park Drive, 4th Floor, Princeton, NJ, USA, 08540

Website

https://www.urogen.com

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

Executives

Mark Schoenberg	officer: Chief Medical Officer	C/O UROGEN PHARMA LTD., 9 HA TA ASIYA STREET, RA ANANA L3 4365007
Jason Drew Smith	officer: General Counsel	C/O UROGEN PHARMA LTD., 400 ALEXANDER PARK DRIVE, PRINCETON NJ 08540
Robinson James A. Jr.	director	852 WINTER STREET, WALTHAM MA 02451
Daniel George Wildman	director	12520 SUNNYDALE DRIVE, WELLINGTON FL 33414
Leana Wen	director	C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672
Dong Kim	officer: Chief Financial Officer	C/O UROGEN PHARMA, LTD., 400 ALEXANDER PARK DRIVE, 4TH FLOOR, PRINCETON NJ 08540
Elizabeth A. Barrett	officer: Chief Executive Officer	C/O UROGEN PHARMA LTD., 9 HA'TA'ASIYA STREET, RA'ANANA L3 4365007
Molly Henderson	officer: Chief Financial Officer	305 COLLEGE ROAD EAST, PRINCETON NJ 08540
Peter P. Pfreundschuh	officer: CFO	C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Stephen Mullennix	officer: COO	C/O UROGEN PHARMA LTD, 9 HA'TA'ASIYA STREET, RA'ANANA L3 4365007
Ran Nussbaum	director	C/O KITE PHARMA, INC., 2225 COLORADO AVENUE, SANTA MONICA CA 90404
Stuart Holden	director	C/O UROGEN PHARMA LTD., 9 HA'TA'ASIYA STREET, RA'ANANA L3 4365007
Cynthia M Butitta	director	3165 PORTER DRIVE, PALO ALTO CA 94304
Ron Bentsur	director, officer: Chief Executive Officer	750 LEXINGTON AVE, 20TH FL, NEW YORK NY 10022
Fred E Cohen	director	301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102